FDA Inspection
Avista Pharma Solutions, Inc. dba CambrexAvista Pharma Solutions, Inc. dba Cambrex – FDA Inspection, May 3, 2024
Record Details
This FDA Inspection record concerns Avista Pharma Solutions, Inc. dba Cambrex, with an inspection on May 3, 2024, issued by the Center for Drug Evaluation and Research, covering drugs.
View Company Profile
ID · d49d28da-b239-4a0c-8f51-8a56a673d5d4
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1237587
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
FDA Citations
4- 21 CFR 211.160(b)Scientifically sound laboratory controls
- 21 CFR 211.194(d)Laboratory equipment calibration records
- 21 CFR 211.22(d)Procedures not in writing, fully followed
- 21 CFR 211.25(a)Training--operations, GMPs, written procedures
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Avista Pharma Solutions, Inc. dba Cambrex
1| Date | Classification | Office | Project area |
|---|---|---|---|
| November 9, 2018 | Not classified | Denver District Office |
Other documents for Avista Pharma Solutions, Inc. dba Cambrex
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.